Wen-Jiao Chang

LukS-PV targets human C5aR1 to reprogram tumor-associated macrophages and potentiate immunotherapy in hepatocellular carcinoma

Immune checkpoint inhibitors (ICIs) benefit only a subset of patients with hepatocellular carcinoma (HCC), largely because of an immunosuppressive tumor microenvironment enriched with M2-like tumor-associated macrophages (TAMs). C5aR1 is highly expressed on HCC TAMs, but no C5aR1-targeted cancer therapy has been...